| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $21.4M | — | +103.4% |
| SG&A Expense | $6.1M | — | +8.2% |
| Operating Income | -$27.5M | — | -70.2% |
| Pre-tax Income | -$24.9M | — | -90.1% |
| Income Tax | $519K | — | +1574.2% |
| Net Income | -$25.4M | — | -93.6% |
| EPS (Basic) | -$10.34 | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $52.9M | +14.9% | — |
| Short-term Investments | $129.7M | -23.7% | — |
| Current Assets | $188.3M | -15.6% | — |
| Total Assets | $227.7M | -8.6% | — |
| Current Liabilities | $14.2M | +11.3% | — |
| Total Liabilities | $18.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.2M | — | +0.2% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $27.9M | — | +112.3% |
| Financing Cash Flow | -$783K | — | — |
| Free Cash Flow | -$20.2M | — | +0.4% |
| -83.0% |
| EPS (Diluted) | -$10.34 | — | -83.0% |
| +10.7% |
| — |
| Stockholders' Equity | -$115.6M | -24.9% | -219.7% |